Who are Rexlemestrocel-L + HA Mixture's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Stempeucel®, ALLO-ASC-DFU, Cx601, FURESTEM-AD Inj., ASCs (Cx401, company code), CARTISTEM® + Debridement.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rexlemestrocel-l-ha-mixture.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Rexlemestrocel-L + HA Mixture — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Rexlemestrocel-L + HA Mixture (Rexlemestrocel-L + HA Mixture) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Allogeneic mesenchymal stem cell therapy. Area: Regenerative Medicine / Orthopedics.

phase 3 Allogeneic mesenchymal stem cell therapy Regenerative Medicine / Orthopedics Small molecule Live · refreshed every 30 min

Target snapshot

Rexlemestrocel-L + HA Mixture (Rexlemestrocel-L + HA Mixture) — Mesoblast, Ltd.. Rexlemestrocel-L is an allogeneic mesenchymal stem cell therapy combined with hyaluronic acid that promotes tissue repair and reduces inflammation through paracrine signaling and immunomodulation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
Rexlemestrocel-L + HA Mixture TARGET	Rexlemestrocel-L + HA Mixture	Mesoblast, Ltd.	phase 3	Allogeneic mesenchymal stem cell therapy
Stempeucel®	Stempeucel®	Cell Biopeutics Resources Sdn Bhd	marketed	Allogeneic mesenchymal stem cell therapy
ALLO-ASC-DFU	ALLO-ASC-DFU	Anterogen Co., Ltd.	phase 3	Allogeneic mesenchymal stem cell therapy
Cx601	Cx601	Tigenix S.A.U.	phase 3	Allogeneic mesenchymal stem cell therapy
FURESTEM-AD Inj.	FURESTEM-AD Inj.	Kang Stem Biotech Co., Ltd.	phase 3	Allogeneic mesenchymal stem cell therapy
ASCs (Cx401, company code)	ASCs (Cx401, company code)	Tigenix S.A.U.	phase 3	Allogeneic mesenchymal stem cell therapy
CARTISTEM® + Debridement	CARTISTEM® + Debridement	Medipost, Inc.	phase 3	Allogeneic mesenchymal stem cell therapy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Allogeneic mesenchymal stem cell therapy class)

Tigenix S.A.U. · 2 drugs in this class
Cell Biopeutics Resources Sdn Bhd · 1 drug in this class
Kang Stem Biotech Co., Ltd. · 1 drug in this class
Anterogen Co., Ltd. · 1 drug in this class
Mesoblast, Ltd. · 1 drug in this class
Pharmicell Co., Ltd. · 1 drug in this class
Medipost, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Rexlemestrocel-L + HA Mixture — Competitive Intelligence Brief. https://druglandscape.com/ci/rexlemestrocel-l-ha-mixture. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing